A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yamashita, Makiko ^a   Kitano, Shigehisa ^b,c   Aikawa, Hiroaki ^a   Kuchiba, Aya ^c   Hayashi, Mitsuhiro ^a,c   Yamamoto, Noboru ^b,c   Tamura, Kenji ^c   Hamada, Akinobu ^a,c  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE ANTIGEN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST TUMOR; CELL CULTURE; CRYOPRESERVATION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MONONUCLEAR CELL; NATURAL KILLER CELL; PHENOTYPE; TUMOR CELL LINE;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, SURFACE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; CRYOPRESERVATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; PHENOTYPE;

EID: 84955498778     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19772     Document Type: Article

References (27)

1. Salinas-Jazmin, N., Hisaki-Itaya, E. & Velasco-Velazquez, M. A. A flow cytometry-based assay for the evaluation of antibodydependent cell-mediated cytotoxicity (ADCC) in cancer cells. Methods Mol Biol 1165, 241-52 (2014).
2. Lesterhuis, W. J., Haanen, J. B. & Punt, C. J. Cancer immunotherapy-revisited. Nat Rev Drug Discov 10, 591-600 (2011).
3. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-12 (1989).
4. Robinson, A. G. et al. Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin Breast Cancer 7, 254-61 (2006).
5. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783-92 (2001).
6. Varchetta, S. et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67, 11991-9 (2007).
7. Nahta, R. Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN Oncol 2012, 428062 (2012).
8. Gennari, R. et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10, 5650-5 (2004).
9. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-7 (2014).
10. Siebert, N., Seidel, D., Eger, C., Juttner, M. & Lode, H. N. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody. PLoS One 9, e107692 (2014).
11. Brunner, K. T., Mauel, J., Cerottini, J. C. & Chapuis, B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Crlabelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14, 181-96 (1968).
12. Jedema, I., Van Der Werff, N. M., Barge, R. M., Willemze, R. & Falkenburg, J. H. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 103, 2677-82 (2004).
13. Derby, E. et al. Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity. Immunol Lett 78, 35-9 (2001).
14. Godoy-Ramirez, K., Franck, K. & Gaines, H. A novel method for the simultaneous assessment of natural killer cell conjugate formation and cytotoxicity at the single-cell level by multi-parameter flow cytometry. J Immunol Methods 239, 35-44 (2000).
15. Nakadate, Y. et al. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. Int J Cancer 134, 2146-55 (2014).
16. Callery, C. D., Golightly, M., Sidell, N. & Golub, S. H. Lymphocyte surface markers and cytotoxicity following cryopreservation. J Immunol Methods 35, 213-23 (1980).
17. Strong, D. M., Ortaldo, J. R., Pandolfi, F., Maluish, A. & Herberman, R. B. Cryopreservation of human mononuclear cells for quality control in clinical immunology. I. Correlations in recovery of K-and NK-cell functions, surface markers, and morphology. J Clin Immunol 2, 214-21 (1982).
18. Hirsen, D. J., Dubin, B. A. & Malham, L. M. Repetitive testing and storage of human effector cells in natural killing and antibodydependent cell-mediated cytotoxicity. Int Arch Allergy Appl Immunol 71, 241-4 (1983).
19. Moller-Larsen, A. et al. Flow cytometric assay detecting cytotoxicity against human endogenous retrovirus antigens expressed on cultured multiple sclerosis cells. Clin Exp Immunol 173, 398-410 (2013).
20. Mata, M. M., Mahmood, F., Sowell, R. T. & Baum, L. L. Effects of cryopreservation on effector cells for antibody dependent cellmediated cytotoxicity (ADCC) and natural killer (NK) cell activity in (51)Cr-release and CD107a assays. J Immunol Methods 406, 1-9 (2014).
21. Costantini, A. et al. Effects of cryopreservation on lymphocyte immunophenotype and function. J Immunol Methods 278, 145-55 (2003).
22. Disis, M. L. et al. Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods 308, 13-8 (2006).
23. Tollerud, D. J. et al. Cryopreservation and long-term liquid nitrogen storage of peripheral blood mononuclear cells for flow cytometry analysis: Effects on cell subset proportions and fluorescence intensity. J Clin Lab Anal 5, 255-61 (1991).
24. Seale, A. C. et al. Effects of cryopreservation on CD4+CD25+T cells of HIV-1 infected individuals. J Clin Lab Anal 22, 153-8 (2008).
25. Sakaguchi, S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22, 531-62 (2004).
26. Mao, Y. et al. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res 20, 4096-106 (2014).
27. Shevach, E. M. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2, 389-400 (2002).